Xenon Pharmaceuticals Inc. (XENE) · Insider trading
What Xenon Pharmaceuticals's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$1.68M
2 insiders, 2 trades
Sold, 12 months
$21.97M
6 insiders, 97% under a plan
Net, 12 months
−$20.29M
bought less sold
Latest filing
2026-10-01
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Mortimer IanDirector, PRESIDENT & CEO | $1.12M | $23.51M | 23 | 2026-09-30 | 49,923 |
| Aulin SherryChief Financial Officer | – | $770,912 | 2 | 2024-12-18 | 0 |
| Kenney Christopher JohnChief Medical Officer | – | $670,288 | 4 | 2026-08-28 | 702 |
| Gannon StevenDirector | – | $640,691 | 2 | 2026-08-11 | 1,870 |
| Kelly Thomas PatrickChief Financial Officer | $559,740 | – | 1 | 2026-09-30 | 15,000 |
| Patou GaryDirector | – | $271,198 | 3 | 2026-06-05 | 24,896 |
| DiFabio AndreaChief Legal Officer | – | $230,825 | 2 | 2026-03-13 | 7,301 |
| Cannon GillianDirector | – | $63,237 | 1 | 2026-06-05 | 1,455 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-09-30 | Mortimer IanDirector, PRESIDENT & CEO | Buy | 30,000 | 37.38 | $1.12M | 49,923 | Form 4 |
| 2026-09-30 | Kelly Thomas PatrickChief Financial Officer | Buy | 15,000 | 37.32 | $559,740 | 15,000 | Form 4 |
| 2026-08-28 | Kenney Christopher JohnChief Medical Officer | Saleplan | 6,368 | 60.17 | $383,163 | 702 | Form 4 |
| 2026-08-28 | Kenney Christopher JohnChief Medical Officer | Saleplan | 700 | 60.98 | $42,686 | 2 | Form 4 |
| 2026-08-11 | Gannon StevenDirector | Sale | 10,000 | 64.06 | $640,600 | 1,870 | Form 4 |
| 2026-06-05 | Cannon GillianDirector | Saleplan | 1,190 | 53.14 | $63,237 | 1,455 | Form 4 |
| 2026-06-05 | Patou GaryDirector | Saleplan | 1,322 | 53.14 | $70,251 | 24,896 | Form 4 |
| 2026-03-13 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 7,308 | 55.23 | $403,621 | 19,923 | Form 4 |
| 2026-03-13 | DiFabio AndreaChief Legal Officer | Saleplan | 1,342 | 55.23 | $74,119 | 7,301 | Form 4 |
| 2026-03-13 | Kenney Christopher JohnChief Medical Officer | Saleplan | 1,410 | 55.23 | $77,874 | 7,069 | Form 4 |
| 2026-03-10 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 11,269 | 60.11 | $677,380 | 14,731 | Form 4 |
| 2026-03-10 | DiFabio AndreaChief Legal Officer | Saleplan | 2,607 | 60.11 | $156,707 | 4,893 | Form 4 |
| 2026-03-10 | Kenney Christopher JohnChief Medical Officer | Saleplan | 2,771 | 60.11 | $166,565 | 4,729 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 21,791 | 58.81 | $1.28M | 59,209 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 31,694 | 59.88 | $1.90M | 27,515 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 21,515 | 60.49 | $1.30M | 6,000 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 12,479 | 59.50 | $742,500 | 18,521 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 10,072 | 60.47 | $609,054 | 8,449 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 2,449 | 61.26 | $150,026 | 6,000 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 43,348 | 59.26 | $2.57M | 72,652 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 61,652 | 60.08 | $3.70M | 6,000 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 65,000 | 62.06 | $4.03M | 6,000 | Form 4 |
| 2026-01-02 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 37,938 | 44.40 | $1.68M | 8,062 | Form 4 |
| 2026-01-02 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 2,062 | 44.93 | $92,646 | 6,000 | Form 4 |
| 2025-12-08 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 8,820 | 45.59 | $402,104 | 8,010 | Form 4 |
| 2025-12-08 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 2,010 | 46.32 | $93,103 | 6,000 | Form 4 |
| 2025-12-05 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 14,375 | 45.03 | $647,306 | 16,830 | Form 4 |
| 2025-11-28 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 97 | 45.01 | $4,366 | 31,205 | Form 4 |
| 2025-10-01 | Mortimer IanDirector, PRESIDENT, CEO & INTERIM CFO | Saleplan | 25,000 | 40.16 | $1.00M | 31,302 | Form 4 |
| 2025-06-05 | Gannon StevenDirector | Sale | 3 | 30.48 | $91 | 7,141 | Form 4 |
| 2025-01-27 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 15,166 | 40.46 | $613,616 | 31,302 | Form 4 |
| 2025-01-27 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 1,149 | 41.07 | $47,189 | 31,302 | Form 4 |
| 2025-01-24 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 22,468 | 40.20 | $903,214 | 31,302 | Form 4 |
| 2025-01-23 | Mortimer IanDirector, PRESIDENT & CEO | Saleplan | 16,217 | 40.08 | $649,977 | 31,302 | Form 4 |
| 2024-12-18 | Aulin SherryChief Financial Officer | Sale | 7,199 | 41.23 | $296,815 | 0 | Form 4 |
| 2024-12-18 | Aulin SherryChief Financial Officer | Sale | 11,510 | 41.19 | $474,097 | 0 | Form 4 |
| 2024-11-22 | Patou GaryDirector | Sale | 2,851 | 41.11 | $117,205 | 23,573 | Form 4 |
| 2024-11-22 | Patou GaryDirector | Sale | 2,040 | 41.05 | $83,742 | 23,573 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
30 × option exercise6 × shares withheld for tax
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-01 | Svoronos DawnDirector | Option exercise M | +5,144 | 8.15 | 31,373 | Form 4 |
| 2026-06-01 | Svoronos DawnDirector | Option exercise M | +2,645 | – | 27,645 | Form 4 |
| 2026-06-01 | Svoronos DawnDirector | Shares withheld for tax F | −1,416 | 53.41 | 26,229 | Form 4 |
| 2026-06-01 | Cannon GillianDirector | Option exercise M | +2,645 | – | 2,645 | Form 4 |
| 2026-06-01 | Gannon StevenDirector | Option exercise M | +2,645 | – | 13,286 | Form 4 |
| 2026-06-01 | Gannon StevenDirector | Shares withheld for tax F | −1,416 | 53.41 | 11,870 | Form 4 |
| 2026-06-01 | Garofalo Elizabeth A.Director | Option exercise M | +2,645 | – | 2,645 | Form 4 |
| 2026-06-01 | Gover Justin D.Director | Option exercise M | +2,645 | – | 2,645 | Form 4 |
| 2026-06-01 | Machado PatrickDirector | Option exercise M | +2,645 | – | 2,645 | Form 4 |
| 2026-06-01 | Patou GaryDirector | Option exercise M | +2,645 | – | 26,218 | Form 4 |
| 2026-05-12 | Gannon StevenDirector | Option exercise M | +3,500 | 7.38 | 10,641 | Form 4 |
| 2026-03-12 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +12,500 | – | 27,231 | Form 4 |
| 2026-03-12 | DiFabio AndreaChief Legal Officer | Option exercise M | +3,750 | – | 8,643 | Form 4 |
| 2026-03-12 | Kenney Christopher JohnChief Medical Officer | Option exercise M | +3,750 | – | 8,479 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +75,000 | 8.40 | 81,000 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +25,000 | 3.10 | 31,000 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +105,000 | 4.75 | 111,000 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +65,000 | 9.44 | 71,000 | Form 4 |
| 2026-03-09 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +20,000 | – | 26,000 | Form 4 |
| 2026-03-09 | DiFabio AndreaChief Legal Officer | Option exercise M | +7,500 | – | 7,500 | Form 4 |
| 2026-03-09 | Kenney Christopher JohnChief Medical Officer | Option exercise M | +7,500 | – | 7,500 | Form 4 |
| 2026-01-02 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +40,000 | 7.49 | 46,000 | Form 4 |
| 2025-10-01 | Mortimer IanDirector, PRESIDENT, CEO & INTERIM CFO | Option exercise M | +25,000 | 7.69 | 56,302 | Form 4 |
| 2025-05-14 | Gannon StevenDirector | Option exercise M | +5,144 | 12.57 | 7,144 | Form 4 |
| 2025-01-27 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +15,166 | 17.76 | 46,468 | Form 4 |
| 2025-01-27 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +1,149 | 17.76 | 32,451 | Form 4 |
| 2025-01-24 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +22,468 | 17.76 | 53,770 | Form 4 |
| 2025-01-23 | Mortimer IanDirector, PRESIDENT & CEO | Option exercise M | +16,217 | 17.76 | 47,519 | Form 4 |
| 2024-12-18 | Aulin SherryChief Financial Officer | Option exercise M | +9,334 | 9.44 | 9,334 | Form 4 |
| 2024-12-18 | Aulin SherryChief Financial Officer | Shares withheld for tax F | −2,135 | 41.28 | 7,199 | Form 4 |
| 2024-12-18 | Aulin SherryChief Financial Officer | Option exercise M | +16,000 | 11.58 | 16,000 | Form 4 |
| 2024-12-18 | Aulin SherryChief Financial Officer | Shares withheld for tax F | −4,490 | 41.28 | 11,510 | Form 4 |
| 2024-11-22 | Patou GaryDirector | Option exercise M | +3,500 | 7.38 | 27,073 | Form 4 |
| 2024-11-22 | Patou GaryDirector | Shares withheld for tax F | −649 | 39.80 | 26,424 | Form 4 |
| 2024-11-22 | Patou GaryDirector | Option exercise M | +3,086 | 13.48 | 26,659 | Form 4 |
| 2024-11-22 | Patou GaryDirector | Shares withheld for tax F | −1,046 | 39.80 | 25,613 | Form 4 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.